All Roads Lead to Change: Addressing Unmet Needs in the African American MS Community
Best Practices in Improving Care Quality and Mitigating Health Disparities from the Multiple Sclerosis Association of America Working Group
Expert Working Group Members | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target Audience
This activity is designed to meet the educational needs of a broad audience of health care providers including pharmacy directors, clinical pharmacists, specialty pharmacists, neurologists, primary care providers, registered nurses, ER providers, social workers, and case managers involved in the treatment and management of Black patients with MS.
Statement of Need/Program Overview
This activity will provide content direction and recommendations for a set of multifaceted interventions to improve the knowledge and performance of MS clinicians that are currently treating, or have the potential to treat, African American MS patients. The anticipated result of these interventions is to better identify and detect early signs of disease progression, along with appropriate and timely therapeutic intervention for the African American MS patient population.
Educational Objectives
ACCREDITATION INFORMATION
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Multiple Sclerosis Association of America, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2618-H01-P
Type of Activity: Knowledge
Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Social Work Education
As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Postgraduate Institute for Medicine maintains responsibility for this course. Social workers completing this course receive 1.0 cultural competency continuing education credits. |
Case Manager Continuing Education
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour(s). Activity code: H00049578 Approval Number: 220000422
To claim these CEs, log into your CCMC Dashboard at www.ccmcertification.org.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Name of Working Group Members/Planners |
Reported Financial Relationship |
Mitzi Joi Williams, MD |
Consulting fees (ex. advisory boards) - Novartis, Biogen, EMD Serono, AbbVie, Genzyme, Bristol Meyers Squibb, Alexion |
Oluwasheyi Akin Ayeni, MD |
Oluwasheyi Akin Ayeni, MD has nothing to disclose. |
Annette Howard, MD |
Consulting fees (ex.advisory boards): EMD Serono, Bristol Myers Squibb, Sanofi Genzyme |
Annette Okai, MD |
Consulting fees (ex.advisory boards): Sanofi Genzyme, Genentech, Biogen, Novartis, EMD Serono |
Angala B. Borders-Robinson, DO, FACN |
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Novartis, Sanofi Genzyme, Genentech |
Jacqueline Faulkner Rosenthal, MD |
Consulting fees (ex.advisory boards): Genentech |
Aljoeson Walker, MD |
Consulting fees (ex.advisory boards): Biogen |
Yolanda Smith Wheeler, PhD, RNP, CPNP-AC, MSCN |
Salary: National MS Society |
Tirisham Gyang, MD |
Consulting fees (ex.advisory boards):EMD Serono, Genentech |
Sophia D. Woodson, CNP |
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Biogen, Genentech, Novartis |
Heidi Crayton, MD |
Consulting fees (ex.advisory boards): Biogen, Bristol Myers Squibb, EMD Serono, Roche |
Angela Lang Chandler, MD |
Consulting fees (ex.advisory boards) – National MS Society, SK Life Science |
The PIM planners and managers have nothing to disclose.
The MSAA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.
MEDIA
Internet